New PET scan for lung tumors using a Nectin-4 probe
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new radioactive imaging agent that targets a protein called Nectin-4, which is often found on lung tumors. The scan will help doctors see if the tumor is visible and how it spreads, which may guide better treatment decisions for lung cancer patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 75 years old.
- Normal heart function as determined by your doctor.
- Expected survival time of at least 12 weeks.
- At least one tumor that can be measured on a CT scan (RECIST criteria).
- Willing and able to follow study procedures and sign a consent form.
- For women who could become pregnant: negative pregnancy test and use of effective contraception; for men: use of effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of PET scan that uses a special tracer to find lung tumors. The goal is to see if this scan can better detect cancer cells, which may help doctors plan the best treatment for you.
This trial tests a new type of imaging scan that uses a special tracer to help doctors see solid tumors more clearly. The scan may help improve how tumors are detected and monitored during treatment.
This trial studies a special PET/CT scan tracer that is designed to bind to a protein (Nectin-4) found in some bladder cancers. It aims to help doctors see and stage tumors more clearly, which could improve diagnosis and treatment planning.
This trial uses a special imaging test (PET/NIR) to find lung cancer cells. It may help doctors see tumors more clearly before and after treatment.
This study uses a special PET/CT scan (called 68Ga-NYM096) to see if it can help find different types of cancer. The scan may help doctors get clearer pictures of where cancer is in your body.
This trial is testing a new imaging probe that binds to EGFR mutations, which are common in some lung cancers. If you have lung cancer with a confirmed EGFR mutation, this scan may help doctors see your cancer more clearly.
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.